The purpose of the study is to find out if budoprutug is safe and well-tolerated in people with this condition, and to see how it affects the body. The study will also look at how the medicine moves through the body over time and whether it can help increase platelet counts. During the study, participants will receive different amounts of budoprutug to help determine which dose works best. Doctors will monitor participants closely to check for any unwanted effects and to measure changes in platelet counts and other blood cells.

Throughout the study, participants will have regular visits where blood samples will be taken to measure platelet levels and other substances in the blood. The study will track how many participants achieve improved platelet counts and whether those taking steroids at the start might be able to stop this treatment. The study will continue for several years to gather information about the long-term effects of budoprutug in people with this blood disorder.

The purpose of this study is to evaluate the long-term safety and how well mezagitamab works in adults who have already participated in previous studies with this medicine and completed those studies. The study will look at whether the treatment causes any unwanted effects over a longer period of time and whether it continues to help maintain platelet counts at safe levels. The study will also examine how long the positive effects on platelet counts last, whether people need fewer other medicines for their condition, and whether they need less emergency treatment for low platelet counts.

During the study, participants will receive mezagitamab through subcutaneous injection, which means the medicine is injected into the tissue just under the skin. The treatment can continue for up to 104 weeks. Throughout the study, doctors will monitor participants for any side effects and measure how the body responds to the treatment by checking platelet counts and other blood tests. The study will also check how the medicine moves through the body and whether the body develops any reaction against the medicine over time.

The treatment being studied is tafasitamab, which is administered through intravenous infusion. This means the medication is delivered directly into a vein over a set period of time. Participants in the study will receive this medication to see how well it helps stabilize blood cell levels and how the body reacts to the drug.

The purpose of this study is to see if a second course of treatment with ianalumab can help people who previously received this medication and experienced improvement but then had their condition return. For people with immune thrombocytopenia, the study will look at whether the second treatment can maintain platelet counts and reduce the need for additional treatments. For people with warm-antibody autoimmune hemolytic anemia, the study will check if the second treatment can maintain hemoglobin levels, which reflects the amount of red blood cells in the blood, and reduce symptoms of anemia.

Participants in this study must have previously taken part in earlier research studies with ianalumab and must have experienced benefit from the treatment but later had their condition worsen. The study will involve receiving ianalumab infusions and regular monitoring visits where blood samples will be taken to measure blood cell counts and check for any side effects. The treatment period will last up to 16 weeks, and participants will be followed for several months afterward to assess how long the benefits last and to monitor safety. During the study, some participants may receive additional supportive treatments or rescue medications if needed to manage their symptoms.

The purpose of the study is to find out if Mezagitamab can help increase the number of platelets in the blood and keep them at a safe level over time in adults with this condition. The study will also look at whether the medicine is safe and how well it works compared to placebo. People taking part may continue some of their current treatments for this condition during the study if their doctor thinks it is appropriate. These might include medicines that help the body make more platelets or certain steroid medicines.

During the study, participants will receive injections of either Mezagitamab or placebo for up to 24 months. Regular blood tests will be done to measure platelet levels, and doctors will check for any bleeding problems or side effects. The study will measure how many people achieve and maintain a platelet count that is considered safe, which is at least 50,000 platelets per microliter of blood. Participants will also be asked about their symptoms and quality of life throughout the study.

The purpose of the study is to find out if adding ianalumab to eltrombopag can help patients go longer without their treatment failing compared to adding placebo to eltrombopag. Treatment failure means that platelet counts remain too low, that rescue treatments are needed, that new treatments for the condition must be started, that the eltrombopag dose cannot be reduced or stopped as planned, or that death occurs. The study will also look at how many patients achieve normal or near-normal platelet counts, how long these improvements last, how safe the treatment is, whether bleeding events occur, and how the treatment affects patients’ daily symptoms like tiredness and overall quality of life.

Patients who join the study will be randomly assigned to receive either ianalumab or placebo, both given along with eltrombopag. The study treatment period will last for several months, during which patients will have regular visits to check their platelet counts, monitor their overall health, and assess any side effects. Blood samples will be taken to measure the levels of certain immune cells and to check how the body processes the study medicine. After the main treatment period ends, patients will continue to be followed to see how long the benefits of treatment last and to monitor their safety.

The purpose of this research is to determine if rilzabrutinib can help maintain higher platelet counts over an extended period in people with ITP. During the study, participants will take rilzabrutinib tablets daily for approximately 80 weeks. The maximum daily dose will be 800 mg.

Throughout the study, participants will have their platelet counts checked regularly to monitor how well the treatment is working. The study will also look at whether the treatment can reduce bleeding problems and allow participants to decrease or stop their corticosteroid medications. Participants’ blood will be tested to check their overall health, including liver and kidney function.

The main purpose of this research is to evaluate how safe and well-tolerated NVG-2089 is when given to patients with ITP. The study will use gradually increasing doses of the medication to understand how patients respond to different amounts. Each participant will receive the treatment through an infusion into their veins.

During the study, researchers will monitor participants’ platelet counts and any side effects that may occur. The treatment period may last several months, during which participants will have regular check-ups to assess their response to the medication. The study will track how well the treatment works by measuring changes in platelet counts and how long the treatment effects last.

The study consists of two parts. In the first part, participants will be randomly assigned to receive either efgartigimod or placebo through regular infusions. Neither the participants nor their doctors will know which treatment they are receiving during this phase. In the second part, all participants will receive the actual medication efgartigimod.

Throughout the study, researchers will monitor how the medication moves through the body, its effects on blood components, particularly platelets and antibodies, and its overall safety. They will also track any bleeding episodes and assess how the treatment impacts the participants’ quality of life. The study will evaluate if efgartigimod can help maintain adequate platelet counts in young patients with chronic ITP.

The purpose of the study is to assess how safe and well-tolerated Pirtobrutinib is in people with ITP and to determine the appropriate doses for further research. The study is divided into two phases. In the first phase, participants will receive different doses of Pirtobrutinib to find the safest and most effective dose. In the second phase, the effectiveness of Pirtobrutinib will be compared to a placebo to see if it helps improve platelet counts in participants.

Participants in the study will take the medication orally and will have regular visits to monitor their health and platelet levels. The study aims to see if Pirtobrutinib can help maintain stable platelet counts without the need for additional treatments. The trial will continue until 2027, with the recruitment of participants expected to start in 2025. This research is important for finding new ways to manage and treat ITP effectively.

The purpose of the study is to evaluate the safety and tolerability of different doses of Budoprutug in people with ITP. Participants will receive Budoprutug through an intravenous infusion, which means the medication will be given directly into a vein. The study will be conducted in phases, starting with smaller doses and gradually increasing to find the most effective and safe dose. Researchers will monitor participants for any side effects and changes in their platelet counts over time.

Throughout the study, researchers will also look at how Budoprutug is processed in the body, including how long it stays in the bloodstream and how it affects the immune system. The study aims to see if Budoprutug can help increase platelet counts and improve the condition of people with ITP. Participants will be observed for any changes in their health and any potential benefits from the treatment. The study is expected to continue until 2028, with recruitment starting in 2025.

The purpose of the study is to evaluate how well belantamab mafodotin works in treating ITP. Participants in the trial will receive the medication in the form of a powder that is mixed into a solution and given through an injection into a vein. The study will monitor participants over a period of time to see how their condition responds to the treatment. Some participants may receive a placebo instead of the actual medication to help compare the effects.

Throughout the study, researchers will keep track of how participants respond to the treatment, including any changes in their platelet counts and any side effects they may experience. The trial aims to provide valuable information on whether belantamab mafodotin can be a safe and effective treatment option for people with Primary Immune Thrombocytopenia.

The purpose of this study is to assess how effective and safe efgartigimod is compared to a placebo. Participants in the study will be randomly assigned to receive either efgartigimod or a placebo, which is a substance with no active medication. The study will begin with a phase where neither the participants nor the researchers know who is receiving the actual treatment or the placebo. This is followed by an open-label phase where all participants will receive efgartigimod. The study will monitor participants over a period to see how well the treatment controls the disease by measuring platelet counts and observing any side effects.

Throughout the study, participants will have regular visits to check their platelet levels and overall health. The goal is to determine if efgartigimod can help maintain platelet counts at a safe level, reducing the risk of bleeding and improving the quality of life for those with ITP. The study will also look at how long it takes for the treatment to start working and how long the effects last. This research aims to provide valuable information on a new potential treatment option for people living with Primary Immune Thrombocytopenia.

The purpose of this research is to determine if combining rituximab with weekly injections of belimumab works better than rituximab with placebo in treating persistent or chronic immune thrombocytopenia. The study will last for 104 weeks (2 years), during which patients will receive either belimumab or placebo injections for 24 weeks, along with two doses of rituximab given early in the treatment period.

Throughout the study, researchers will monitor platelet levels, immune system components, and overall health status. The treatment involves subcutaneous (under the skin) injections of belimumab or placebo, while rituximab is given through intravenous administration. Patients will have regular check-ups to monitor their response to treatment and any potential side effects.

The purpose of the study is to evaluate the safety and effectiveness of efgartigimod in adult patients with Primary Immune Thrombocytopenia. Participants in the study will receive the treatment over a long-term period, and the study will monitor how well the treatment works and how safe it is for the patients. The study will also look at how the treatment affects platelet counts, which are important for blood clotting, and will track any side effects or adverse events that may occur during the treatment period.

Throughout the study, participants will have regular visits to check their health and monitor their response to the treatment. The study aims to provide valuable information on the potential benefits and risks of using efgartigimod for treating Primary Immune Thrombocytopenia, helping to determine if it can be a safe and effective option for patients with this condition.

The first treatment combination consists of intravenous immunoglobulin given through a vein along with oral prednisone tablets taken daily for three weeks. The second treatment option involves high-dose dexamethasone tablets taken for four days. Both treatments aim to increase the number of platelets in the blood and reduce bleeding symptoms.

The study will track how quickly patients respond to treatment over the first five days, particularly looking at improvements in platelet counts and reduction in bleeding. Patients will be monitored for six months to evaluate the long-term effectiveness of both treatments. Throughout the study, doctors will regularly check platelet counts and assess any bleeding symptoms.

Participants in the study will be randomly assigned to receive either Rituximab or Avatrombopag. The study will last for several months, during which time participants will have regular check-ups to monitor their platelet levels and overall health. The goal is to see if either treatment can help maintain a healthy platelet count without the need for additional medications. Participants will also be asked about their quality of life and any side effects they experience during the study.

This trial aims to provide valuable information on the effectiveness of these two treatments for ITP, potentially leading to better management options for patients with this condition. The study will help determine which treatment might be more beneficial in maintaining platelet levels and improving the quality of life for those affected by ITP.

The purpose of the study is to explore the safety and effectiveness of Rilzabrutinib in adults with ITP who have not responded well to previous treatments. The study is divided into two parts. In the first part, different doses of Rilzabrutinib will be tested to find the most suitable dose. In the second part, the focus will be on a specific dose to see how well it works over a longer period. Participants will take the medication and have regular check-ups to monitor their platelet levels and any side effects they might experience.

Throughout the study, researchers will pay close attention to how the participants’ platelet counts change and whether they experience any side effects from the medication. The goal is to determine if Rilzabrutinib can help increase platelet counts and reduce bleeding symptoms in people with ITP. Participants will be monitored closely to ensure their safety and to gather information on how well the treatment works over time.

Participants in the study will be randomly assigned to receive either Rilzabrutinib or a placebo, which looks like the real medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the initial phase. The study will last for a total of 24 weeks, with an additional open-label extension where all participants may receive Rilzabrutinib. The main goal is to see if Rilzabrutinib can help maintain a stable platelet count without the need for additional rescue treatments.

Throughout the study, participants will have regular check-ups to monitor their platelet levels and overall health. The trial aims to provide valuable information on how well Rilzabrutinib works in managing ITP and its safety profile. This research could potentially lead to new treatment options for those living with this condition.

The purpose of the study is to evaluate the safety and tolerability of Povetacicept in individuals with these autoimmune conditions. Participants in the study will receive Povetacicept and will be monitored to assess how their bodies respond to the treatment. The study will look at various factors, including any side effects that may occur and how the medication affects the participants’ health over time.

Throughout the study, participants will receive regular check-ups and assessments to ensure their well-being and to gather information on the effectiveness of the treatment. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. This trial aims to provide valuable insights into the potential benefits and risks of using Povetacicept for treating autoimmune cytopenias.

The purpose of this study is to evaluate the long-term safety of efgartigimod in adult patients with primary immune thrombocytopenia. Participants in the study will receive efgartigimod infusions and will be monitored over a period of time to assess how safe the treatment is and how well it works in managing the condition. The study will involve regular visits to the clinic for infusions and check-ups, where doctors will keep track of the participants’ health and any changes in their platelet counts.

Throughout the study, researchers will collect information on the frequency and severity of any side effects, as well as changes in vital signs and laboratory test results. The study aims to provide valuable insights into the long-term use of efgartigimod for treating primary immune thrombocytopenia, helping to determine if it is a safe and effective option for patients with this condition.

The purpose of the study is to assess how well platelets function after taking a 75 mg dose of aspirin. Participants in the study will take aspirin daily, and researchers will measure the production of a substance called thromboxane B2 by the platelets 24 hours after taking the aspirin. Thromboxane B2 is a chemical that helps platelets stick together and form clots. The study will also look at platelet function using a method called light transmission aggregometry, which helps understand how well platelets are working.

The study will follow participants over a period of time to observe any changes in platelet function and to identify any occurrences of arterial thrombosis, which is a type of blood clot in the arteries. The study aims to provide insights into how aspirin affects platelet function in patients with immune thrombocytopenia and cardiovascular disease, potentially helping to improve treatment strategies for these conditions.

Participants in the study will receive the PF-06835375 Injection over a period of 12 weeks. The study will monitor the participants’ platelet counts, which are important for blood clotting, at different points during the study. The goal is to see if the treatment can help increase platelet counts and improve the condition of those with ITP. Another medication, Diphenhydramine Hydrochloride, which is commonly used as an antihistamine, may also be used in the study.

The study will involve regular visits to the clinic for monitoring and assessments. Participants will be closely observed for any side effects or changes in their condition throughout the study period. The information gathered from this study will help determine the potential benefits and risks of using PF-06835375 Injection as a treatment for Primary Immune Thrombocytopenia.

The purpose of the study is to evaluate whether the combination of romiplostim and dexamethasone is more effective than dexamethasone alone in achieving a sustained response in patients, meaning that their platelet levels remain stable without the need for additional ITP treatments. The study will observe patients over a period of time to see if they can maintain healthy platelet levels and avoid significant bleeding episodes. Participants will receive either the combination treatment or dexamethasone alone, and their progress will be monitored by healthcare professionals.

Throughout the study, patients will be regularly assessed to ensure their safety and to track the effectiveness of the treatments. The study will last for several months, with the goal of determining which treatment option provides the best long-term results for individuals with newly diagnosed primary immune thrombocytopenia. This research is important for improving treatment strategies and outcomes for people affected by this condition.

The purpose of the study is to evaluate how well these medications work together in treating patients with immune thrombocytopenia. Participants in the study will receive one or more of these medications, or a placebo, over a period of time. The study will monitor the participants’ platelet counts and other health indicators at various points to assess the effectiveness of the treatment. The study will also look at the number of patients who achieve remission, meaning their symptoms improve without the need for ongoing therapy.

Throughout the study, participants will have regular visits to check their health and progress. The study will also collect information on the quality of life of participants before, during, and after treatment. This information will help researchers understand the impact of the treatment on daily living. The study aims to provide valuable insights into the management of immune thrombocytopenia and improve treatment options for patients with this condition.